6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OFFOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2023

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

ThreeInternational Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F   ☑                 Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 16, 2023, Kazia Therapeutics Limited (the “Company”) issued an ASX announcement titled, “Kazia Raises A$4.5 Million to Progress R&D Programs.” A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-259224).

EXHIBIT LIST

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EX-99.1

Exhibit 99.1

January 16, 2023

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Sydney, January 16, 2023 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors in Australia, at a price of A$0.11 per share. The placement will raise A$4.5 million (exclusive of costs).

Placement

The Placement to professional and sophisticated investors consists of an:

The price of both the Unconditional Placement and the Conditional Placement will be A$0.11 which represents a 13% premium to the 15-day volume-weighted average price (VWAP) on the Australian Securities Exchange (ASX) up to and including 11 January 2023 of A$0.097.

New Shares to be issued under the Unconditional Placement will be issued without shareholder approval under the Company’s existing placement capacity under ASX Listing Rules 7.1. Settlement and issuance of shares is expected to occur on or around January 16, 2023, with quotation expected on January 17, 2023 in Australia. The New Shares will rank equally with the Company’s existing shares on issue.

An Extraordinary General Meeting (EGM) is expected to be held on 24 February 2023 to seek approval for the issuance of New Shares under the Conditional Placement. Kazia will provide eligible shareholders with a notice of meeting and explanatory materials over the coming days.

The Placement was not underwritten.

Funding will be used to drive Kazia’s clinical program toward several critical inflection points, including the final data read out on the paxalisib GBM AGILE study.

[ENDS]

This announcement may include forward-looking statements, which can generally be identified assuch by the use of words such as “ may, ” “ will, ” “ estimate, ” “ future, ” “ forward, ” expect, ” “ anticipate, ” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions,expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding the placement of shares and the company ’ splans with respect to the proceeds from the placement . These forward-looking statements are based on Kazia ’ s expectations and beliefs concerning future events. Forward-looking statements are necessarilysubject to risks, uncertainties and other factors, many of which are outside the control of Kazia , which could cause actual results to differ materially from such statements. These and other risks and uncertainties are describedmore fully in Kazia ’ s Annual Report, filed on Form 20-F with the Securities and Exchange Commission (SEC), and in other filings with the SEC. Kazia makes noundertaking to subsequently update or revise the forward-looking statements made in this announcement, to reflect the circumstances or events after the date of this announcement. You should not place undue reliance on these forward-lookingstatements, whi ch apply only as of the date of this announcement.

This release does not constitute an offer to sell, or a solicitation ofan offer to buy, securities in the United States or to U.S. persons (as defined in Rule 902 under the Securities Act of 1933, as amended (the Securities Act)), or for the account or benefit of U.S. persons. The securities referred to in thisannouncement have not been registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States. Accordingly, such securities may not be offered or sold, directly or indirectly, in the UnitedStates or to any U.S. persons or to any person acting for the account or benefit of a U.S. person, except in transactions (i) registered under the Securities Act or (ii) exempt from, or not subject to, the registration requirements of theSecurities Act and any other applicable securities laws of any state or other jurisdiction of the United States.